Is the use of secukinumab after anti-TNF therapy greater than expected for the risk of developing inflammatory bowel disease? Fatih Albayrak; Mustafa Gür; Ahmet Karata¿; Süleyman Serdar Koca; Bünyamin K¿sac¿k;

Secukinumab as biological treatment for psoriatic arthritis in real clinical practice José A. Pinto Tasende; Francisco J. Maceiras Pan; José A. Mosquera Martínez; Luis Fernández Dominguez; Blanca Correa Rey; Carlos García Porrúa;

Patients with spondyloarthritis including psoriatic arthritis: Current needs, impact, and perspective Estíbaliz Loza; Pedro Plazuelo; Ceade;